Could HLA-type be the answer to individual differences in COVID-19 severity?

The COVID-19 pandemic has changed the world. While vaccines are now being approved, a true understanding of the biological processes underlying COVID-19 and why some individuals develop severe disease while others are asymptomatic is necessary. HLA-type could be a key differentiator in disease outcomes, and in developing treatments.

HLA-COVID

The Coronavirus disease 2019 (COVID-19) pandemic continues to have significant global impact and understanding the underlying biological causes of the disease and in particular why some patients suffer serious illness while others have mild or asymptomatic disease is of significant importance. COVID-19 is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multiple factors are associated with disease outcomes. Research so far suggests human leukocyte antigen (HLA)-type could be a key differentiator between patients who experience different morbidity and mortality when infected with SARS-CoV-2. If this is the case, it could be possible to identify individuals at greater risk form the disease and explain differences in the epidemic trend in different countries. It could also help in development of novel vaccines to prevent COVID-19.

The HLA is a critical component of the viral antigen presentation pathway in humans and the HLA gene locus plays a fundamental role in human adaptive immunity. Genetic variability across the HLA alleles is known to be associated with outcomes in many different diseases and could be a key determinant in susceptibility to and severity of COVID-19. For example, HLA class I receptors which present antigen to cell-destroying cytotoxic T cells have three types, A, B and C. In any individual each HLA class I type has an allele from each parent. Different alleles result in different variants of the HLA class I receptor, which can recognise different foreign proteins as antigen. Research has found that patterns of variation in HLA type can be seen within populations and countries, suggesting a given population will respond differently to a given virus depending on the HLA alleles found in that population.

Individual genetic variation in HLA-type may help to explain different immune responses to a virus across a population. HLA-type influences the T-cell-mediated response to viral infection, and is therefore implicated in the morbidity and mortality of SARS-CoV-2 infection. Patients with severe cases of COVID-19 have been shown to be suffering from a dysregulated adaptive immune response (Yu, 2020; Giamarellos-Bourboulis, 2020), which could be mediated via HLA type as individuals with different HLA types respond differently to the same viral antigen (Crux, 2017). A small study early in the COVID-19 pandemic found HLA-A*01:01 and HLA-A*02:01 correlated with number and severity of infections in Italy (Pisanti, 2020). In another study, researchers found homozygous HLA class I genes resulted in poor prognosis, except for specific HLA alleles which resulted in a lower risk of death (Shkurnikov, 2020). In a study of 82 Chinese patients HLA type was associated with COVID-19 occurrence (Wang, 2020). Other studies have also found associations with HLA type and disease occurrence and morbidity, although at this stage most sample sizes are relatively small and further research in large, varied populations is required.

This research will likely prove worthwhile. The differences in the morbidity and mortality of COVID-19 patients are striking with studies showing 18-30% of individuals are asymptomatic to SARS-CoV-2 infections (Warren, 2020) while others suffer severe and even fatal disease. The mortality rate is around 3.4% (Warren, 2020). Many factors have been implicated in severity of disease from age, sex and race to occupation (Mutambudzi, 2020). It’s possible HLA type intersects with other factors to result in a combined risk factor for severe disease. Identifying specific HLA-types that influence the morbidity and mortality would allow identification of people and populations at greater risk if they were to become infected. Considering the relative ease and low cost of HLA-typing, a comprehensive understanding of HLA-type associations with population risk of disease could greatly improve public health measures to combat the COVID-19 pandemic (Nguyen, 2020).

Research is ongoing to understand how HLA-type may be associated with COVID-19 outcomes. The huge molecular variability of HLA alleles and single nucleotide polymorphisms (SNPs) means a significant effort is needed to truly understand the role of HLA-type in COVID-19 pathogenesis and epidemiology. Understanding who is most likely to become infected with SARS-CoV-2, and who is most at risk of severe outcomes and even death could help decision making around who gains access to early vaccines as they come available. As the most efficient way to combat viruses is via our own immune system, HLA peptide binding and T-cell response assays could help develop further effective vaccines to prevent spread of the disease entirely. As we begin to bring COVID-19 under control, thoughts turn to the potential role for HLA type in future disease outbreaks where an early understanding of how these receptors impact disease outcomes could help prevent unnecessary mortality via public health measures and develop new treatments specific to HLA-type.

Products for Respiratory Research

Human respiratory tract
Human respiratory tract
PromoCell human primary airway cells are available from nasal, tracheal and bronchial epithelia
Product Cat. No
Human Nasal Epithelial Cells (HNEpC) C-12620
Human Tracheal Epithelial Cells (HTEpC) C-12644
Human Bronchial Epithelial Cells (HBEpC) C-12640
Human Small Airway Epithelial Cells (HSAEpC) C-12642
Airway Epithelial Cell Growth Medium C-21060
Small Airway Epithelial Cell Growth Medium C-21070

We offer a wide range of characterized primary cells for respiratory research together with optimized cell culture media. We have HNEpC, HSAEpC, HPMEC, and HPF from donors who have tested negative for SARS-CoV-2 and the option of a high resolution 4-digit HLA typing report for all primary cells. Find out more at www.promocell.com

 

References

  • Crux NB & Elahi S (2017) Human Leukocyte Antigen (HLA) and Immune Regulation: How do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections? Front Immunol 8:832.
  • Evangelos J.Giamarellos-Bourboulis Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
  • Mutambudzi M, Niedwiedz C, Macdonald EB, et al. (2020) Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occupational & Environmental Medicine http://dx.doi.org/10.1136/oemed-2020-106731
  • Nguyen A, David JK, Maden SK, et al. (2020) Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. Journal of Virology DOI: 10.1128/JVI.00510-20
  • Pisanti S, Deelen J, Gallina AM, et al. (2020) Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. Journal of Translational Medicine 18:352
  • Shkurnikov, M. et al. (2020). Association of HLA class I genotypes with age at death of COVID-19 patients. medRxiv doi: https://doi.org/10.1101/2020.11.19.20234567.
  • Wang W, Zhang W, Zhang J, et al. (2020) Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease‐2019 (COVID‐19). HLA 96(2):194-196.
  • Warren R, Birol I 2020 Retrospective in silico HLA predictions from COVID-19 patients reveal alleles associated with disease prognosis. 2020 Nov 2;2020.
  • Warren R, Birol I 2020 HLA predictions from the bronchoalveolar lavage fluid and blood samples of eight COVID-19 patients at the pandemic onset. 2020 Aug 27;btaa756
  • Yu K, Jingjing H, Yongjian W, et al. 2020 Dysregulated adaptive immune response contributes to severe COVID-19. Cell Research 30:814-816.

Tell us your HLA donor requirements

Please give us your contact details. One of our scientific specialists will get in touch to handle your request.

Contact Us

Choose your Region

Please choose your region for an optimized website experience. So we can provide you with the most useful information for your country.

  1. North America
    1. Canada
    2. United States
  2. Europe
    1. Albania
    2. Austria
    3. Belgium
    4. Bosnia-Herzogovina
    5. Bulgaria
    6. Croatia
    7. Czech Republic
    8. Denmark
    9. Finland
    10. France
    11. Germany
    12. Greece
    13. Hungary
    14. Ireland
    15. Italy
    16. Liechtenstein
    17. Luxembourg
    18. Macedonia
    19. Monaco
    20. Netherlands
    21. Norway
    22. Poland
    23. Portugal
    24. Romania
    25. Serbia
    26. Slovakia
    27. Slovenia
    28. Spain
    29. Sweden
    30. Switzerland
    31. United Kingdom
  3. Asia
    1. Bangladesh
    2. China
    3. Hong Kong (incl. Macau)
    4. India
    5. Indonesia
    6. Israel
    7. Japan
    8. Malaysia
    9. Nepal
    10. Singapore
    11. South Korea
    12. Sri Lanka
    13. Taiwan
    14. Thailand